Engaged Capital’s Puma Biotechnology PBYI Stock Holding History

Engaged Capital’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-151,689	Closed	-$6.96M	–	17
2018 Q3	$6.96M	Buy	+151,689	New	+$7.31M	0.98%	14

Other funds holding PBYI

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Engaged Capital's PBYI Position: Q4 2018 in Review

Engaged Capital sold out of Puma Biotechnology (PBYI) in Q4 2018, closing a stake of 151,689 shares — an estimated $6.96M sold.

Engaged Capital first reported a position in PBYI in Q3 2018 and held it in 1 quarter. The position peaked at $6.96M in Q3 2018. 141 funds tracked by Wall St. Rank hold PBYI as of Q4 2018.

Engaged Capital reported no remaining Puma Biotechnology position as of Q4 2018 after selling out during the quarter.
Engaged Capital sold 151,689 Puma Biotechnology shares in Q4 2018, an estimated $6.96M.
Engaged Capital first reported a position in Puma Biotechnology in Q3 2018 and held it in 1 quarter.
Engaged Capital's Puma Biotechnology position peaked at $6.96M in Q3 2018.
141 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2018.

Based on Engaged Capital's 13F filing for Q4 2018, filed 14 Feb 2019.